Arda Durmaz
Overview
Explore the profile of Arda Durmaz including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
37
Citations
247
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Ogbue O, Bahaj W, Kewan T, Ahmed R, Dima D, Willimas N, et al.
J Intern Med
. 2023 Nov;
295(2):229-241.
PMID: 37953670
Background: Splenectomy is commonly used to treat refractory immune-mediated cytopenia, but there are no established factors that are associated with response to the procedure. Objectives: A cohort study was conducted...
12.
Mori M, Kubota Y, Durmaz A, Gurnari C, Goodings C, Adema V, et al.
Leukemia
. 2023 Aug;
37(10):2082-2093.
PMID: 37634012
Complete or partial deletions of chromosome 7 (-7/del7q) belong to the most frequent chromosomal abnormalities in myeloid neoplasm (MN) and are associated with a poor prognosis. The disease biology of...
13.
Bahaj W, Kewan T, Gurnari C, Durmaz A, Ponvilawan B, Pandit I, et al.
J Hematol Oncol
. 2023 Aug;
16(1):91.
PMID: 37537667
Background: TP53 mutations (TP53) occur in diverse genomic configurations. Particularly, biallelic inactivation is associated with poor overall survival in cancer. Lesions affecting only one allele might not be directly leukemogenic,...
14.
Attardi E, Savi A, Borsellino B, Piciocchi A, Cipriani M, Ottone T, et al.
Blood Adv
. 2023 Jun;
7(17):5122-5131.
PMID: 37327116
The increasing knowledge of molecular genetics of acute myeloid leukemia (AML) necessitated the update of previous diagnostic and prognostic schemes, which resulted in the development of the World Health Organization...
15.
Kewan T, Durmaz A, Bahaj W, Gurnari C, Terkawi L, Awada H, et al.
Nat Commun
. 2023 May;
14(1):3136.
PMID: 37253784
Genomic mutations drive the pathogenesis of myelodysplastic syndromes and acute myeloid leukemia. While morphological and clinical features have dominated the classical criteria for diagnosis and classification, incorporation of molecular data...
16.
Ogbue O, Unlu S, Ibodeng G, Singh A, Durmaz A, Visconte V, et al.
Cancers (Basel)
. 2023 May;
15(9).
PMID: 37173944
Acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) are genetically complex and diverse diseases. Such complexity makes challenging the monitoring of response to treatment. Measurable residual disease (MRD) assessment is...
17.
Gurnari C, Prata P, Catto L, Durmaz A, Larcher L, Sebert M, et al.
Blood
. 2023 Apr;
141(25):3122-3125.
PMID: 37053552
No abstract available.
18.
Maltas J, Tadele D, Durmaz A, McFarland C, Hinczewski M, Scott J
bioRxiv
. 2023 Mar;
PMID: 36993678
The evolution of resistance remains one of the primary challenges for modern medicine from infectious diseases to cancers. Many of these resistance-conferring mutations often carry a substantial fitness cost in...
19.
Bahaj W, Kewan T, Gurnari C, Durmaz A, Ponvilawan B, Pandit I, et al.
Res Sq
. 2023 Mar;
PMID: 36945617
mutations ( ) occur in diverse genomic configurations. Particularly, biallelic inactivation is associated with poor overall survival in cancer. Lesions affecting only one allele might not be directly leukemogenic, questioning...
20.
Durmaz A, Gurnari C, Hershberger C, Pagliuca S, Daniels N, Awada H, et al.
iScience
. 2023 Mar;
26(3):106238.
PMID: 36926651
RNA splicing dysfunctions are more widespread than what is believed by only estimating the effects resulting by splicing factor mutations (SF) in myeloid neoplasia (MN). The genetic complexity of MN...